The company also announced profitability will be achieved by the 3Q of 2025, a goal the broker believes is achievable, with the key trigger being approval for Recell Go, due on
The analysts leave the $6.40 target unchanged and suggest post-result share price weakness is a great buying opportunity. Add.
Sector: Pharmaceuticals, Biotechnology & Life Sciences.
Target price is
© 2024 Acquisdata Pty Ltd., source